HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with...

Related Keywords

Hong Kong ,United Kingdom ,China ,Tongji ,Sichuan ,France ,Spain ,United States ,Shanghai ,Huazhong ,Hubei ,Italy ,Japan ,American ,Chinese ,Ben Atwell Alex Shaw ,Zhou Yi ,Mark Lee ,Ren Chi Yang ,Michael Shi ,Annie Cheng ,Huazhong University Of Science ,National Medical Products Administration Of China ,Nasdaq ,Practice Research Database ,Linkedin ,American Society Of Hematology ,Steering Committee ,Chinese Academy Of Medical Sciences ,Institute Of Hematology ,Tongji Medical College ,China Limited ,Union Hospital ,Stock Exchange Of Hong Kong ,European Union Withdrawal ,Exchange Commission ,New Drug Application ,National Medical Products Administration ,Breakthrough Therapy ,Lancet Haematology ,Chief Medical Officer ,Blood Diseases Hospital ,Chinese Academy ,Medical Sciences ,Leading Principal Investigator ,Huazhong University ,Securities Litigation Reform Act ,Stock Exchange ,Hong Kong Limited ,European Union ,Senior Vice ,Alex Shaw ,Freddy Crossley ,Daphne Zhang ,American Society ,Therapeutic Mechanisms ,Immune Thrombocytopenia ,Med Res ,United Kingdom General Practice Research ,Immune Thrombocytopenic Purpura ,Nasdaq Hcm ,Hutchmed China Limited ,